FTRE

Rating buyAI Memo

Fortrea

As of 2026-08-03/Confidence medium

Open ticker Back to Memos

Data freshness

AI Memo

As of 2026-08-03 • Model: RankAlpha Sentiment Codex

Decision Panel

Action, confidence, horizon, and decision blockers at a glance.

Action

buy

Confidence

medium

Horizon

—

Key catalyst

Execution against upgraded FY2026 guidance • 2026-12-31

Expected move: +10%

Biggest risk

Revenue still declined year over year, FSP and pass-through headwinds remain, and the newly appointed CFO cannot currently serve because of an ongoing restrictive-covenant proceeding; an interim CFO is serving [#EARNINGS-TRANSCRIPT-2026Q2]. Analyst estimate revisions and post-print target changes are unavailable.

Invalidation

Break below $16 or thesis failure.

What would change my mind?

The Q2 print showed improving adjusted profitability, four consecutive quarters with book-to-bill above 1.0x, and a raised FY2026 outlook. Continued bookings and backlog conversion could support a modest rerating [#SEC-8K-2026-07-29].

Research note

Recommendation

buy

Confidence

medium

As of

2026-08-03

Base target

$21

p=55%

Bull target

$24

p=25%

Bear target

$16

p=20%

Key bullets

Fast scan of bull, bear, and watch items

BullKey bullets

Raised FY2026 outlook and positive booking cadence
Biotech demand and clinical-pharmacology conversion
The Q2 print showed improving adjusted profitability, four consecutive quarters with book-to-bill above 1.0x, and a raised FY2026 outlook.

BearKey bullets

Analyst revision data, post-print price reaction, and social coverage are unavailable; forward visibility remains limited.
CFO leadership uncertainty could complicate execution or investor confidence [#EARNINGS-TRANSCRIPT-2026Q2].
Failure to convert bookings and backlog into the raised FY2026 outlook could reverse the post-earnings improvement.

WatchKey bullets

Execution against upgraded FY2026 guidance

Summary

High-level snapshot

Recommendation

buy

Model confidence

medium

Timeframe

Asset

Equity

Trigger

Base case: $21 (p=55%)

Bull/Bear spread: +25% / -19%

Vs latest close: Bull +25% · Base +10% · Bear -19%

Scenario probabilities

Bull Target: $24 (p=25%)Base Target: $21 (p=55%)Bear Target: $16 (p=20%)

Commentary

The available post-earnings tone is cautiously positive because guidance was raised and adjusted operating metrics improved, but revenue remains in decline and CFO uncertainty is material. No reliable post-release price reaction, analyst revision set, options data, short-interest data, employee score, or social coverage was provided; missing reaction data is not positive evidence.

As of 2026-08-03 • Updated bi-weekly / post-earningsSource: Internal modelMethodology

Analyst Summary

Thesis highlights from the latest analysis

Bull Case

Bear Case

Drivers

Scannable catalysts and supporting factors

Raised FY2026 outlook and positive booking cadence
Biotech demand and clinical-pharmacology conversion

Scenarios

Bull Target (Scenario probability)

$24 / p=25% prob

Base Target (Scenario probability)

$21 / p=55% prob

Bear Target (Scenario probability)

$16 / p=20% prob

Price $19 as of 2026-07-31

Nearest Scenario: Base (∆ 10%)

Targets vs latest close: Bull +25% · Base +10% · Bear -19%

Sentiment & Exposure

News Sentiment (30d)

0.65

Social Sentiment (7d)

0.00

Events

Other notable items detected

EVENT2026-12-31
Execution against upgraded FY2026 guidance
Sustained commercial execution, backlog conversion, cost savings, and margin expansion would support further rerating if Fortrea delivers the increased full-year outlook [#SEC-8K-2026-07-29] [#EARNINGS-TRANSCRIPT-2026Q2].
Prob 55.00% • Move 12.00% • Priced-in 40.00%

Short-term Catalysts

Next few weeks

Raised FY2026 outlook and positive booking cadence
2026-08-31
Q2 revenue was $678.2 million, adjusted EPS was $0.23 versus $0.19 a year earlier, adjusted EBITDA was $58.7 million versus $54.9 million, and book-to-bill was 1.06x. Management raised FY2026 revenue guidance to $2.62-$2.69 billion and adjusted EBITDA guidance to $205-$220 million [#SEC-8K-2026-07-29].
Prob 70% • Move 8% • Priced-in 55%

Long-term Catalysts

Months to a year

Biotech demand and clinical-pharmacology conversion
2027-06-30
Stored Q2 earnings context indicates $720.4 million of net new business, a 1.12x trailing-twelve-month book-to-bill ratio, and strength in clinical pharmacology and biotech demand. The thesis depends on converting awards into revenue while maintaining operational discipline [#SEC-8K-2026-07-29] [#PR-EARNINGS-2026-07-29].
Prob 45% • Move 20% • Priced-in 30%

Risks

Analyst revision data, post-print price reaction, and social coverage are unavailable; forward visibility remains limited.
CFO leadership uncertainty could complicate execution or investor confidence [#EARNINGS-TRANSCRIPT-2026Q2].
Failure to convert bookings and backlog into the raised FY2026 outlook could reverse the post-earnings improvement.
GAAP net loss remained negative despite improved adjusted earnings and EBITDA [#SEC-8K-2026-07-29].
Revenue declined 4.5% year over year in Q2, with continued FSP and lower pass-through-cost headwinds [#SEC-8K-2026-07-29].

Peers

Symbol	Summary
ANIP	Loose same-sector and similar-market-cap comparator; useful for small-cap life-sciences valuation context but not a direct CRO operating peer.
IOVA	Loose same-sector and similar-market-cap comparator; development-stage biotech economics differ materially from Fortrea's contract-research-services model.

Sources

Internal and external references used in this analysis

Model source: RankAlpha Sentiment Codex
Analysis date: 2026-08-03

AI Stock Memo: FTRE - Fortrea - RankAlpha